A double-blind, placebo-controlled evaluation of the efficacy and safety of loreclezole as add-on therapy in patients with uncontrolled partial seizures

• Published in: Epilepsy research Vol. 9; no. 1; pp. 59 - 64
• Main Authors: Rentmeester, T, Janssen, A, Hulsman, J, Scholtes, F, van der Kleij, B, Overweg, J, Meijer, J, de Beukelaar, F
• Format: Journal Article
• Language: English
• Published: Amsterdam Elsevier B.V 01.05.1991; Elsevier
• Subjects: Add-on; Adult; Anticonvulsants - adverse effects; Anticonvulsants - blood; Anticonvulsants - therapeutic use; Anticonvulsants. Antiepileptics. Antiparkinson agents; Biological and medical sciences; Double-blind; Double-Blind Method; Drug Interactions; Epilepsies, Partial - drug therapy; Female; Follow-Up Studies; Humans; Loreclezole; Male; Medical sciences; Neuropharmacology; Partial seizure; Pharmacology. Drug treatments; Safety; Time Factors; Trial; Triazoles - adverse effects; Triazoles - blood; Triazoles - therapeutic use; Partial seizure; Add-on; Trial; Double-blind; Loreclezole; Human; Chemotherapy; Nervous system diseases; Treatment; Partial; Epilepsy; Controlled therapeutic trial; Anticonvulsant; Negative therapeutic reaction
• ISSN: 0920-1211; 1872-6844
• DOI: 10.1016/0920-1211(91)90047-J

Sixty-two patients with uncontrolled partial seizures participated in a 12-week, double-blind, placebo-controlled add-on trial. Thirty-two patients received loreclezole and 30 a placebo as add-on therapy. Loreclezole was targeted at a plasma level of 1–2 mg/1. In spite of an antiepileptic therapy, usually with 2 or 3 antiepileptic drugs, these patients had at least 4 seizures a month during the baseline period. At the end of the treatment phase with loreclezole and placebo, individual responses varied widely. The median change in the daily seizure frequency was not significantly different in the 2 groups. However, when individual responses are considered, 6 patients in the verum group (19%) experienced a seizure reduction of 50% or more, compared with no patients in the placebo group. During the trial, only mild adverse events were reported in both the loreclezole and the placebo group, nor were any clinically relevant abnormalities seen in the haematological and biochemical analysis. The efficacy and safety of higher loreclezole plasma concentrations were studied in a long-term follow-up trial, the results of which are presented in the following article.